Marcos Sintes, Syn2Psy ESR5, is one of the authors of a study recently posted as preprint on BioRxiv, on the potential effects of psilocybin for the therapy of autism spectrum disorder (ASD).
The autors used valproic acid-exposed mice as a model of ASD and assessed the effects of the naturally occurring psychedelic prodrug psilocybin. They found that psilocybin rescued the social behavioural abnormalities present in these mice, suggesting that it may be a promising pharmacotherapy for altered sociability in ASD.
Abstract: Autism spectrum disorder (ASD) is characterized by core deficits in social interaction. The classic serotonergic psychedelic psilocybin has been suggested as a therapeutic agent that may ameliorate in the core symptomology of ASD. We found that the acute response to psilocybin was attenuated in the prenatal valproic acid exposure mouse model of ASD, and importantly, psilocybin rescued the social behavioural abnormalities present in these ASD model mice.
You can find the full posted article here: https://www.biorxiv.org/content/10.1101/2020.09.09.289348v1